Quantitative analysis predicts the relative therapeutic efficacy of different forms of CTLA4Ig
Authors:
- 31 December 2011
- journal article
- research article
- Published by Elsevier in Molecular Immunology
- Vol. 49 (3) , 527-536
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- CTLA-4: a key protein in autoimmunityNature Reviews Rheumatology, 2009
- Abatacept Does Not Induce Direct Gene Expression Changes in Antigen-Presenting CellsJournal of Clinical Immunology, 2009
- Interaction of human PD-L1 and B7-1Molecular Immunology, 2008
- Update on Abatacept: A Selective Costimulation Modulator for Rheumatoid ArthritisAnnals of Pharmacotherapy, 2007
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- CTLA4Ig: Bridging the Basic Immunology with Clinical ApplicationImmunity, 2006
- The immunological synapse and CD28-CD80 interactionsNature Immunology, 2001
- CTLA-4 (CD152) Can Inhibit T Cell Activation by Two Different Mechanisms Depending on Its Level of Cell Surface ExpressionThe Journal of Immunology, 2000
- Structure and Function of Sphingolipid- and Cholesterol-rich Membrane RaftsJournal of Biological Chemistry, 2000
- Models for the Specific Adhesion of Cells to CellsScience, 1978